Volume : 10, Issue : 06, June – 2023
Title:
09.FORMULATION AND EVALUATION OF SUSTAINED RELEASE AMBROXOL HCL TABLETS BY USING NATURAL POLYMERS
Authors :
Dr. M.Hareesh Reddy, Shaziya Takreem, Shaziya Begum , Mir Shahanawaz Ali, Sumera Jabeen, Shaik Khalid
Abstract :
The main objective is to formulate and evaluate the ambroxol Hcl sustained release matrix tablets for treating bronchial asthma and chronic bronchitis. In addition, the oral medication is generally considered as the first avenue investigated in the discovery and development of new drug entities and pharmaceutical formulations, mainly because of patient acceptance, convenience in and cost-effective manufacturing process. Ambroxol hydrochloride tablets were prepared by direct compression method by using natural polymers like Xanthane gum, Gum karaya and Guargum. The prepared matrix tablets were tested for evaluation parameters such as drug content, hardness, friability, weight variation, in-virto drug release and release kinetics. The formulation F showed better sustained release of about 99.81% and follows Higuchi order with high regression value of 0.993 with complete drug release in 12 hrs made it to select as an optimized formulation compared with other formulations. Thus it was selected for in vivo investigation.
Keywords: Ambroxol hydrochloride, Sustain release, Xanthane gum, Gum karaya and Guargum.
Cite This Article:
Please cite this article in press M.Hareesh Reddy et al, Formulation And Evaluation Of Sustained Release Ambroxol Hcl Tablets By Using Natural Polymers., Indo Am. J. P. Sci, 2023; 10 (06).
Number of Downloads : 10
References:
1) Chien Y. W., “Novel Drug Delivery System” (IInd Edn), Revised and expanded, 1992, p.no.139-140.
2) Remington, “The Science and Practice of pharmacy”, 20th Edn, vol.I, p.no.903-913
3) Brahmankar D. M. and Jaiswal S .B. in “Biopharmaceutics and Pharmacokinetics”, “A Treatise,” Vallabh Prakashan, 1st edn, 1995, p.no.347- 352.
4) Lee V. H., Robinson J. R. in, “Sustained and Controlled Release Drug Delivery System,” Marcel Dekker, New York, p.no. 71-121.,138-171
5) Lachman Leon, Liberman H.A.and Kanig J.L., “The Theory and Practice of Industrial pharmacy” (3rd Edn), Varghese publishing House Bombay, p.no.430
6) RuggeroBettini, www.medfarm uniforit/pharmaco/itcis/Erasmus/ erasm13, html [7k.
7) J. Lapidus, N. G. Lordi, in , “Journal Of Pharm. Sci.”, 1991-1992,(8), p.no 86.
8) Liberman, H. A. “Pharmaceutical Dosage Form; Tablets,” second Edn, Vol. I, p.no. 136.
9) Aulton M.E. “Hand Book of pharmaceutics Edition” 2001, p.no.291-295.
10) Howard C.Ansel “Pharmaceutical Dosage Form and Drug Delivery, Systems”, (7th edition) p.no.229-243.
11) Jain N.K., “Controlled and Novel Drug Delivery” CBS 1-2, 2002, P.no.676-698.
12) Roopa S. Ghirnikar, Yuen L. lee and Lawrence F. Eng , Spinal Cord Injury: Hope for a cure, Indian J.Pharm.Sci., 2001, 63(5),p.no. 349-363.
13) Yihong Qui, Howard Cheskin,” sustained release hydrophilic matrix tablets of zileuton: formulation and in vitro/ in vivo studies”, J. Cont. Rel., 1997(45),p.no.249-256.
14) S. Indiran Pather, Irina Tussell, James A. Syce,” sustained release theophylline by direct compression formulation and in vitro evaluation,” Int. J. Pharm. 1998, 168, p. No. 1-10.
15) S .K. Baveja, A. V. Hassan and Amarjit Singh in, “Ind. J. Pharm. Sci,” 1989, 55,p.no. 249-250
16) Philip J. Cox, Karrar A. Khan, Dale L. Munday, in, “Int. J. Pharm” 1999 193 p.no. 73-84.
17) Yoshiteru Watanabe, Tatsuya Ishikawa, Hisashi Endo, Mitsuo Matsumoto,in, “Int. J. Pharm” 2000,202 p. no-173-178.
18) Leopoldo Villafuerte, Rogelio Espinoza, Enrique Hong, in “Int. J. Pharm. 2000),201 p. no 165-173.
19) J. L. Pedraz ,M. A. Solinis, Y. De La Cruz, A. R. Gascon, in , “ Int. J. Pharm. 2002,239, p. no. 60-62.
20) I. Haririan, A. ghaffari and M. mohammad-pour, in, “Ind. J. Pharm. Sci.2001, 63(1) p.no. 24-29.
21) Tiwari S. B, T. Krishna Murthy, M. Raveendra Pai, Pavak R. Mehta, in, “AAPS Pharm. Sci. Tech.2003, 4(3) article 31 p. no. 1-6.
22) Jaber Emami and Naser Tavakoli, in, “J. Pharm. Pharmaceut. Sci., 2004, 7(3):p.no. 338-344
23) N. Patra , M. E. Bhanoji Rao, k. s. Yadhav, K. Prakash, in, “Ind. J. Pharm. Sci, (2004), 66(5) p. no. 636-641
24) Nandi P.K., “studies on fabrication of Ibruprofen SR product and its release pattern,” “Indian Drugs,” 1996, 35(5), p.no 64-68
25) Haider S.S., Monujan N., and Shahriyar S.M., “Sustained release preparation of metclopramide Hcl based on fatty matrix,” “Indian drugs” 2002,39(2), p.no.73-79.
26) S. Vidyadhara, P. Rama Rao and J.A. Prasad, in, “Ind. J. Pharm. Sci., 2004,66(2), p. no 188-192.
27) Ashish Heda and Umesh Shivhare, in, “Int. J. Pharma. Exp” 2004, p. no. 69-74.
28) Dhake A.S. and Behl A.K., in, “Indian Drugs” 2005, 42(5), p. no. 316-318.
29) Tetsuo Hayashi, Hideyoshi Kanbe, Minoru Okada, in “Int. J. Pharm” 2005,304,p. no. 91-101.
30) P.M. Dandagi, V. S. Mastiholomath, M. B. Patil, F. V. Manvi, in, “Ind. J. Pharm. Sci”, 2005, 67(5), p. no. 598-602.